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Abstract
Lys-g3-MSH is a melanocortin peptide derived from the
C-terminal of the 16 kDa fragment of POMC. The
physiological role of Lys-g3-MSH is unclear, although it
has previously been shown that, although not directly
steroidogenic, it can act to potentiate the steroidogenic
response of adrenal cortical cells to ACTH. This synergistic
effect appears to be correlated with an ability to increase the
activity of hormone sensitive lipase (HSL) and therefore the
rate of cholesterol ester hydrolysis. Ligand binding studies
have suggested that high-afﬁnity binding sites for Lys-g3-
MSH exist in the adrenal gland and a number of other rat
tissues that express HSL, including adipose, skeletal muscle
and testes. To investigate the hypothesis that Lys-g3-MSH
may play a wider role in cholesterol and lipid metabolism, we
tested the effect of Lys-g3-MSH on lipolysis, an HSL-
mediated process, in 3T3-L1 adipocytes. In comparison with
other melanocortin peptides, Lys-g3-MSH was found to be a
potent stimulatorof lipolysis. It was also able to phosphorylate
HSL at key serine residues and stimulate the hyper-
phosphorylation of perilipin A. The receptor through
which the lipolytic actions of Lys-g3-MSH are being
mediated is not clear. Attempts to characterise this receptor
suggest that either the pharmacology of the melanocortin
receptor 5 in 3T3-L1 adipocytes is different from that
described when expressed in heterologous systems or the
possibility that a further, as yet uncharacterised, receptor
exists.
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Introduction
The a-, b-a n dg-melanocyte-stimulating hormones (MSHs)
are melanocortin peptides that are derived from the adreno-
corticotrophin (ACTH) precursor proteinpro opiomelanocor-
tin (POMC). Unlike a-MSH, which was puriﬁed from
pituitary extracts, the sequence of g-MSH was predicted from
the gene sequence of POMC (Nakanishi et al.1 9 7 9 ). Based on
the location of the putative dibasic residue cleavage sites, three
related peptides (g1, g2a n dg3-MSH) have been described.
Subsequent studies where the peptides have been isolated
from pituitary extracts have shown that the Arg-Lys site at the
N-terminal of g-MSH is, in fact, cleaved after the arginine
residue resulting in all the peptides carrying an additional
lysine at their N-terminus (Bohlen et al. 1981, Browne et al.
1981). These studies have also shown that g2-MSH does not
exist and that the bulk of g-MSH in the anterior pituitary
consists of pro-g-MSH (corresponding to N-POMC 1–74 in
rodents), whilst the intermediate lobe processes POMC to
mainly Lys-g3-MSH (corresponding to N-POMC 50–74)
and small amounts of Lys-g1-MSH (Zhou et al. 1993). In
addition, unlike the other melanocortin peptides, both
pro-g-MSH and Lys-g3-MSH carry an N-linked glycan at
their C-terminus (corresponding to residue 65 of POMC).
In comparison with a-MSH and ACTH, the g-MSH
peptides have received relatively little attention and their




1981). Studies performed in the early 1980s have shown that
both pro-g-MSH and Lys-g3-MSH, although not directly
steroidogenic, are able to potentiate the steroidogenic response
of rat adrenal cells to ACTH (Pedersen & Brownie 1980,
Pedersen et al.1 9 8 0 , Al-Dujaili et al.1 9 8 1 ). This synergistic
effect appears to be correlated with an ability to increase
the activity of the enzyme hormone sensitive lipase (HSL;
Pedersen et al.1 9 8 0 ). HSL acts to catalyse the hydrolysis of
cholesterol esters and triacylglycerides, with the hydrolysis of
cholesterol esters vital for steroidogenesis in the adrenal cortex,
ovaryandtestesandthehydrolysisoftriacylglyceridescentralto
lipolysis in adipose tissue (Yeaman 2004). HSL has also been
shown to regulate the hydrolysis of cholesterol esters and
triacylglycerides in the heart, pancreas, skeletal muscle and
macrophage cells (Small et al.1 9 8 9 , 1991, Langfort et al.1 9 9 9 ,
Mulder et al.1 9 9 9 ).
In 1983, before the identiﬁcation of the ﬁve members of
the melanocortin receptor (MC-R) family, Pedersen &
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g-MSH receptor expressed by the adrenal gland. They
showed that rat adrenal cortex membrane preparations
possessed high-afﬁnity binding sites for radio-labelled
synthetic Lys-g3-MSH that are distinct from ACTH binding
sites (Pedersen & Brownie 1983). To their surprise, they also
found that binding was not conﬁned to the adrenal gland.
Indeed, in comparison with the adrenal gland, they observed
higher levels of binding in rat adipose tissue, skeletal muscle
and testes membrane preparations and lower levels of binding
in rat cardiac muscle, ovary and spleen membrane
preparations (Pedersen & Brownie 1983). These observations
led Pedersen & Brownie 1983 to hypothesise that the actions
of g-MSH peptides on HSL activity, and therefore
cholesterol and lipid utilisation, may not be limited to the
adrenal gland.
The high level of speciﬁc binding sites for Lys-g3-MSH on
adipose tissue (Pedersen & Brownie 1983) suggests that the
g-MSH peptides may be able to regulate HSL activity in this
tissue and therefore be lipolytic. The melanocortin peptides,
ACTH, a-MSH and b-lipotrophin, have long been known to
promote lipolysis, to varying degrees, in the adipocytes
of various mammalian species (White & Engel 1958,
Ramachandran & Lee 1976, Ramachandran et al. 1976,
Boston 1999). However, upon an extensive literature review,
onlyonestudy(Ng1990)canbefoundshowingthatg1-MSH
(without the N-terminal lysine) is very weakly lipolytic in
rabbit adipocytes. In this present study, we present results that
support the hypothesis that the actions of g-MSH peptides are
notlimitedtotheadrenalglandbydemonstratingthatLys-g3-
MSH potently stimulates lipolysis in 3T3-L1 adipocytes.
Although the lipolytic activity of Lys-g3-MSH suggests that
HSLisbeingactivated,wealsodirectlyinvestigatedtheactions
of this peptide, and other melanocortin peptides, on HSL
phosphorylation and another protein central to the lipolytic
process, perilipin A.
Finally, the speciﬁc receptor for Lys-g3-MSH implicated in
the binding study by Pedersen & Brownie (1983) remains
unidentiﬁed.WiththesubsequentidentiﬁcationoftheMC-Rs,
it has been shown that 3T3-L1 adipocytes express only the
MC2-R and MC5-R (Boston & Cone 1996)f o rw h i c h
g-MSH has no signiﬁcant or limited afﬁnity respectively
(Griffon et al.1 9 9 4 , Schioth et al.1 9 9 5 , 1996). The limited
afﬁnity of g-MSH for the MC2-R and MC5-R has led us to
investigate the properties of the receptor that mediates the
lipolytic action of Lys-g3-MSH on 3T3-L1 adipocytes.
Materials and Methods
Growth and differentiation of the 3T3-L1 cell line
Cryopreserved 3T3-L1 pre-adipocytes were obtained from the
ECACC. The cells were maintained in a humidiﬁed incubator
at37 8Cwith5%CO 2ingrowthmediaconsistingofDulbecco’s
modiﬁed Eagle’s medium(DMEM; Sigma) supplementedwith
10% (v/v) calf serum (Invitrogen), L-glutamine (2 mM) and
penicillin/streptomycin (100 U/ml; Invitrogen) and sub-
cultured every 2–3 days. Stocks of 3T3-L1 pre-adipocytes
from early passage were stored at K70 8C in calf serum
supplemented with 10% DMSO (Sigma).
To differentiate 3T3-L1 pre-adipocytes into adipocytes,
cells were grown to conﬂuence in six-well plates (w6.3!10
5
cells), and 2 days later differentiation was induced (day 0) by
the addition of growth media containing 10% foetal bovine
serum (FBS; Invitrogen) in place of calf serum supplemented
with 3-isobutyl-1-methylxanthine (0.5 mM; Sigma), insulin
(1.7 mM; Sigma) and dexamethasone (1 mM; Sigma). After
2 days, the media was changed to FBS growth media
supplemented with just insulin (1.7 mM) and maintained for a
further 2 days. On day 4, the media was changed to just FBS
growth media and subsequently changed every second day.
Differentiation from pre-adipocyte to adipocyte occurred
generally 1–2 days after the insulin was removed. On day 8,
the cells were serum starved overnight in DMEM
supplemented with L-glutamine (2 mM) and penicillin/strep-
tomycin (100 U/ml; Invitrogen) and experiments conducted
on day 9.
Investigating the actions of various melanocortin peptides on
glycerol release from 3T3-L1 adipocytes
Onday9,serumstarved3T3-L1adipocytes(w6.3!10
5)were
washed thrice with phenol red-free Hank’s balanced salt
solution (HBSS; Sigma). Peptides of interest were prepared in
Glycerol Assay Solution (phenol red-free HBSS supplemented
with 0.5% BSA (Sigma) and penicillin/streptomycin
(100 U/ml; Invitrogen)) and added to the adipocytes in 2 ml
volumes.Aftertheadditionofpeptides,thecellswereincubated
for 4 h in a humidiﬁed incubator at 37 8Cw i t h5 %C O 2.
Following incubation, the media was harvested and glycerol
content measured using a sequential enzymatic assay based on
that described in Sharma et al.( 1 9 8 7 )except that N-ethyl-N-
(2-hydroxy-3-sulphopropyl)-3-methylaniline (Dojindo, NBS,
Biologicals, Huntingdon, UK) was used instead of sodium
2-hydroxy-3,5-dichlorobenzenesulphonate.
In each experiment, the lipolytic response of 3T3-L1
adipocytes to test peptides was determined in triplicate for
each dose tested and compared with the control level within
that experiment. The control level was determined in each
experiment from three responses that did not receive any
peptide treatment. Cell number was determined from six
random wells per experiment using a haemocytometer after
the removal of the Glycerol Assay Solution. The lipolytic
response of 3T3-L1 adipocytes to test peptides is expressed as
glycerol release (fold above control), per 4-h incubation, per
6.3!10
5 cells. Results were analysed using GraphPad Prism
(Graphpad Software, San Diego, CA, USA) and are presented
as ﬁtted dose–response curves showing meansGS.E.M. of the
number of responses tested.
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Lys-g3-MSH was puriﬁed to homogeneity from bovine
pituitary tissue (Pel-Freez Biologicals, Rogers, AZ, USA)
using ion exchange and reversed-phase HPLC as previously
described (Bennett 1986) and quantiﬁed using amino acid
analysis. NDP-a-MSH, a-MSH HS024 and ACTH1–24 were
obtained from Bachem (St Helens, UK).
Raising and puriﬁcation of an HSL-speciﬁc antibody
The C-terminal fragment of mouse HSL corresponding to
residues 536–739 was ampliﬁed by PCR and cloned into the
pET32a vector (Novagen, Nottingham, UK) to generate a
fusion protein with thioredoxin at the N-terminal and a 6!
His tag between the two protein partners. After expression in
Origami (DE3) pLysS cells (Novagen), recombinant HSL
fusion protein was harvested in 8 M Urea and subsequently
puriﬁed to homogeneity using immobilised metal-ion afﬁnity
chromatography and anion exchange chromatography. The
puriﬁed HSL fusion protein (50 mg per injection) was mixed
with Freund’s incomplete adjuvant and injected (1 ml total
per animal) into three different female rabbits (New Zealand
White; Charles River, Kent, UK). Animals were injected and
bled as previously described (Bicknell et al. 2001). All
procedures were carried out under the UK Animals
(Scientiﬁc Procedures) Act (1986). The antibody was then
afﬁnity puriﬁed from serum by afﬁnity chromatography using
the HSL fusion protein covalently linked to CnBr-activated
sepharose resin (Sigma). The bound antibody was eluted
using a stepwise protocol as previously described in
Hodgkinson & Lowry (1982). Puriﬁed antibody amount
was determined by spectrophotometric analysis, and the
speciﬁcity of the HSL antibody generated was assessed by
westernblotof various ratand mouse tissues (data not shown).
Evaluation of HSL and perilipin A phosphorylation
On day 9, serum-starved 3T3-L1 adipocytes that had been
differentiated in six-well plates were incubated for 20 min
with Glycerol Assay Solution containing either Lys-g3-MSH,
ACTH, a-MSH or NDP-a-MSH at a dose of 1 pM, 10 pM,
100 pM, 1 nM, 10 nM and 100 nM.
After incubation, protein was harvested by lysing the cells
directly in 200 mlo f1 ! Reducing Sample Treatment Buffer
(50 mMTris–HCl(pH6.8),0.1 M dithiothreitol(Sigma), 2%
(w/v) SDS (Sigma), 0.01% bromophenol blue (Sigma) and
10% (v/v) glycerol (Fisher, Loughborough, UK)). After brief
sonication, and boiling at 94 8C for 5 min, 5 ml of each sample
was separated on a 6.5% (perilipin A) or 10% (HSL) SDS-
PAGE gel and transferred to polyvinylidene ﬂuoride (PVDF)
membrane (Bio-Rad). The membrane was blocked by
incubating with Tris-buffered saline (10 mM Tris–HCl (pH
7.4), 150 mM sodium chloride) containing 5% skimmed
milk powder and 0.1% Tween 20 (Sigma) for 2 h at room
temperature.Afterblocking,themembraneswereprobedwith
either a perilipin-speciﬁc antibody (Abcam, Cambridge, UK)
at a 1:2000 dilution, the HSL-speciﬁc antibody described
above, at a 1:2000 dilution, or the phospho-HSL-speciﬁc
antibodies: HSLphos660, HSLphos563 and HSLphos565 at a
1:2000 dilution (Cell Signalling Technology (NEB), Hitchin,
UK). All primary antibodies were then detected using a horse
radish peroxidase (HRP)-conjugated secondary goat anti-
rabbit antibody (Dako, Ely, UK) and visualised using an ECL
system, as per manufacturer’s instructions (Amersham). All
blots were carried out on a minimum of three independent
samples.
After immunoblotting,bandswereanalysedbydensitometry
using a GS-710 calibrated imaging densitometer (Bio-Rad).
Statistical analysis of results
Statistical analysiswas performed using one-way ANOVA and
Fisher’s PLSD test. Results were considered statistically
signiﬁcant if the P value was !0.05. Statistical analysis was
performed using StatView software version 5.0.1 SAS
Institute Inc., Cary, NC, USA).
Results
Comparison of the lipolytic actions of melanocortin peptides on
3T3-L1 adipocytes
To investigate the hypothesis proposed by Pedersen &
Brownie (1983) that g-MSH peptides may be able to regulate
the activity of HSL in tissues other than the adrenal gland, we
compared the lipolytic activity of Lys-g3-MSH, a-MSH,
NDP-a-MSH and ACTH on 3T3-L1 adipocytes. As can be
seen in Fig. 1, all the peptides stimulated an increase in
lipolysis in a dose-dependent manner with ACTH (BMax
6.58G0.16!control values) and Lys-g3-MSH (BMax 7.26G
18!control values) producing the largest maximal responses,
although ACTH was more potent (EC50 248G45 pM) than
Lys-g3-MSH (EC50 3.56G0.47 nM). a-MSH was not as
potent (EC50 4.50G1.35 nM) nor able to induce the levels of
lipolysis (BMax 4.68G0.22!control values) seen in response
to a maximal dose of Lys-g3-MSH or ACTH. Surprisingly,
NDP-a-MSH, a peptide that has been shown to be a potent
agonist at all of the MC-Rs (with the exception of the
MC2-R; Schioth et al. 1996, Haskell-Luevano et al. 2001)
produced only a modest increase in lipolysis (BMax 2.05G
0.07!control values), but was more potent than any of the
other peptides tested (EC50 4.19G1.69 pM).
The effect of Lys-g3-MSH on the phosphorylation state of HSL
The ability of Lys-g3-MSH to increase the rate of liploysis
suggests that this peptide is able to regulate the activity of
HSL. The activity of HSL is primarily regulated by reversible
phosphorylation mechanisms (Holm 2003). We therefore
investigated the ability of Lys-g3-MSH and ACTH to
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phosphorylation sites using immunoblotting and phospho-
speciﬁc antibodies. Based on densitometry of the bands, we
found that Lys-g3-MSH was able to signiﬁcantly phosphory-
late HSL at serine residues 660 at doses of 100 pM (P!0.05)
or above (P!0.01) and 563 at a dose of 1 nM or above
(P!0.01), while ACTH phosphorylated serine 660 at a dose
of 100 pM or above (P!0.01) and 563 at doses of 100 pM or
above (P!0.01). Both Lys-g3-MSH and ACTH resulted in a
signiﬁcant (P!0.01) reduction in the basal phosphorylation
state of serine 565 (Fig. 2). NDP-a-MSH and a-MSH were
not able to stimulate phosphorylation of serine 660 or 563 at
any of the doses tested, nor did they have any effect on the
basal phosphorylation of serine 565 (results not shown).
The effect of melanocortin peptides on the phosphorylation state
of perilipin A
Within the last 10 years, it has become clear that activation of
HSL on its own is not enough for maximal lipolysis to occur
(Tansey et al.2 0 0 1 , 2003, Souza et al.2 0 0 2 ). A further protein,
perilipin A, must also be activated (Souza et al.2 0 0 2 , Sztalryd
etal.20 03 ,Tansey etal.2003).Initsunstimulatedstate,perilipin
AactstoguardthelipiddropletfromtheactivityofHSL(Souza
et al.2 0 0 2 , Tansey et al.2 0 0 3 ) and upon stimulation, becomes
hyperphosphorylated and moves away from the lipid droplet,
allowing HSL access to its substrate (Tansey et al.2 0 0 3 ). In the
unphosphorylated state, perilipin A migrates under reducing
conditions on an SDS-PAGE gel as a 62 kDa protein and upon
hyperphosphorylation, it migrates as a 67 kDa protein (Souza
et al.2 0 0 2 , Tansey et al.2 0 0 3 ).
We investigated the actions of Lys-g3-MSH, ACTH,
a-MSH and NDP-a-MSH on the phosphorylation status of
perilipin A in 3T3-L1 adipocytes. In unstimulated cells,
perilipin was detected at 62 and 47.5 kDa (Fig. 3A). The
62 kDa band represented perilipin A and the 47.5 kDa band
most likely represented perilipin D (an isoform of perilipin
generated by alternative splicing; Servetnick et al. 1995).
Treatment of 3T3-L1 adipocytes with doses of ACTH at
10 pM or above resulted in a signiﬁcant shift (PZ0.0194) in
the migratory rates of perilipin A from 62 to 67 kDa (Fig. 3A
and B). Lys-g3-MSH caused a signiﬁcant (PZ0.0022) shift at
a dose of 1 nM or above (Fig. 3A and B), while a-MSH
caused a signiﬁcant (PZ0.0061) shift at a dose of 10 nM or
above (Fig. 3A and B). NDP-a-MSH was not able to cause a
signiﬁcant shift in the migratory rate of perilipin A at any dose
tested (Fig. 3A and B).
Antagonistic action of NDP-a-MSH on a-MSH but not
Lys-g3-MSH or ACTH stimulated lipolysis
The observation that Lys-g3-MSH stimulates lipolysis in
3T3-L1 adipocytes indicates the presence of a receptor for the
peptide in this cell line. These cells have been shown to only
express the MC2-R and MC5-R (Boston & Cone 1996) for
which g-MSH peptides have no signiﬁcant or limited afﬁnity
respectively (Griffon et al. 1994, Schioth et al. 1995, 1996).
The limited afﬁnity of these receptors for g-MSH peptides
suggests that they are unlikely to play a role in mediating the
lipolytic actions of Lys-g3-MSH.
In 1996, Boston & Cone (1996) attempted to characterise
the roles played by the MC2-R and MC5-R in mediating the
actions of a-MSH and ACTH on cAMP accumulation in
3T3-L1 adipocytes. They observed that NDP-a-MSH,
although binding with high afﬁnity, was unable to stimulate
cAMP accumulation. They also found that it could act as an
antagonist of a-MSH, but not ACTH, induced cAMP
accumulation (Boston & Cone 1996). In a similar manner,
our results show that NDP-a-MSH is a weak, but potent,
stimulator of lipolysis (Fig. 1) indicating that NDP-a-MSH
has high afﬁnity for a receptor site, presumably the MC5-R,
but cannot act to fully stimulate lipolysis.
In an attempt to characterise the receptor that mediates the
actions of Lys-g3-MSH, we tested the ability of
NDP-a-MSH to act as an antagonist to the lipolytic actions
of Lys-g3-MSH and other melanocortin peptides. 3T3-L1
adipocytes were stimulated with a maximal dose of ACTH
(100 nM), Lys-g3-MSH, (100 nM) or a-MSH (1 mM), in the
presence or absence of an increasing dose of NDP-a-MSH
(Fig. 4). NDP-a-MSH at all doses caused a slight, but
signiﬁcant (PZ0.0061, 0.0068, and 0.0077), reduction in the
lipolytic activity of ACTH (Fig. 4). In comparison, NDP-a-
MSH at 1 or 10 nM had no effect on the lipolytic activity of
Lys-g3-MSH but at 100 nM did cause a slight, but signiﬁcant
(PZ0.0265), reduction in lipolytic activity (Fig. 4). In direct
contrast, NDP-a-MSH had a much more profound effect on
the lipolytic actions of a-MSH (Fig. 4). NDP-a-MSH at all
doses tested caused signiﬁcant (P!0.0001) reductions in the
lipolytic action of a-MSH (Fig. 4). NDP-a-MSH at 100 nM
Figure 1 Lys-g3-MSH, ACTH, a-MSH and NDP-a-MSH are able to
increase lipolysis in 3T3-L1 adipocytes. Results are presented as
glycerol release (fold above control), per 4 h, per 6.3!10
5 cells.
Each data point is the mean of the number of responses tested and
the error bars represent meanGS.E.M. Curves were ﬁtted using
GraphPad Prism and used to calculate EC50 and BMax values for
each peptide.
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ACTH or Lys-g3-MSH, to the level seen in response to
NDP-a-MSH at 100 nM alone (Fig. 4).
Antagonistic action of HS024, an MC1, MC3, MC4 and
MC5 receptor antagonist on a-MSH but not Lys-g3-MSH
or ACTH stimulated lipolysis
Since NDP-a-MSH was able to act as an antagonist of the
actions of a-MSH, we decided to investigate the effects on
lipolysis of HS024, another antagonist that has potent actions
on the MC1, MC3, MC4 and MC5-R receptors (Kask et al.
1998). In a similar manner to NDP-a-MSH, HS024 at a dose
of 100 nM was found to weakly, but signiﬁcantly
(P!0.0001), stimulate lipolysis (Fig. 5). When HS024 was
administered with 1 nM a-MSH, there was no change in
lipolysis when compared with administration of either
a-MSH or HS024 alone. However, co-administration of
HS024 with 10 nM a-MSH had the effect of reducing
signiﬁcantly (P!0.0001) lipolytic activity when compared
with 10 nM a-MSH alone.
Interestingly, when HS024 was administered in conjunction
with1 nMpuriﬁedLys-g3-MSH,itwasfoundthattherewasan
additive effect resulting in a signiﬁcant (P!0.0001) increase in
lipolytic activity compared with that observed with either
HS024 or Lys-g3-MSH alone. However, HS024 had no effect
on the lipolysis induced by 10 nM Lys-g3-MSH.
Administration of HS024 together with 1 nM ACTH
resulted in a small but signiﬁcant (PZ0.0033) decrease in
lipolysis when compared with that induced by 1 nM ACTH
alone, although HS024 had no effect on lipolysis induced by
10 nM ACTH.
Figure 2 Representative immunoblots showing the effects of (A) Lys-g3-MSH and (B) ACTH on the phosphorylation state of HSL at speciﬁc
serineresiduesin 3T3-L1adipocytes.Thephosphorylationstate ofHSL wasdetermined,aftera 20-minstimulationinthe presence orabsence
of Lys-g3-MSH or ACTH at increasing dose from 1 pM to 100 nM, byanalysing the degree of phosphorylation of serine residues 563, 565 and
660 using antibodies speciﬁc for each phosphorylated serine site. (0), no peptide added. Densitometric analysis was performed on the results
of three independent experiments and is presented as the means of the phosphorylated HSL content divided by the mean of the total HSL
content for the same sample. The error bars represent the meanGS.E.M.* P!0.05 and **P!0.01 indicate a signiﬁcant difference from the
corresponding untreated value.
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www.endocrinology-journals.org Journal of Endocrinology (2008) 196, 149–158Figure 3 (A) Analysis of the effect of Lys-g3-MSH, ACTH, a-MSH and NDP-a-MSH on the phosphorylation state of perilipin A in 3T3-L1
adipocytes. The phosphorylation state of perilipin A was determined by analysing the migratory rate of perilipin A, on 6.5% SDS-PAGE gels,
either 62 kDa (unstimulated) or 67 kDa (stimulated, hyperphosphorylated). (K), no peptide added. (0), time point zero. (B) Densitometric
analysis of the effect of Lys-g3-MSH, ACTH, a-MSH and NDP-a-MSH on the phosphorylation state of perilipin A in 3T3-L1 adipocytes. The
phosphorylation state of perilipin A was determined by analysing the migratory rate of perilipin A, on 6.5% SDS-PAGE gels, either 62 kDa
(unstimulated) or 67 kDa (stimulated, hyperphosphorylated). All results presented, except those at time point 0 (0) and (K) (no peptide
added), are the average of three responses from independent experiments. Results presented at time point (0) and (K) are the average of 12
responses from three independent experiments. The error bars represent the mean GS.E.M. (a) (PZ0.0194) is signiﬁcantly different from the
control(K) value.(b) (PZ0.0022)is signiﬁcantlydifferentfromthecontrol(K)value.(c)(PZ0.0061)is signiﬁcantlydifferentfromthecontrol
(K) value.(d) (PZ0.004)is signiﬁcantlydifferentfromthecontrol(K)value.*(P!0.0001)indicatesthatvaluesaresigniﬁcantlydifferentfrom
the control (K) value.
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Elegant studies carriedout by Pedersen&Brownie (1980) and
Al-Dujaili et al. (1981) demonstrated that g-MSH peptides
have the ability to potentiate the steroidogenic activity of
ACTH at the adrenal gland. It was demonstrated that this
ability was the result of an increase in the activityof HSL – the
enzyme that converts cholesterol esters to free cholesterol
(Pedersen & Brownie 1980). Subsequent ligand binding
studies showed the existence of binding sites for Lys-g3-MSH
on a number of other tissues leading to the hypothesis that
g-MSH peptides may have an extra-adrenal activity (Pedersen
& Brownie 1983). Since the highest binding levels were
observed on adipocyte membrane preparations (Pedersen &
Brownie 1983), we investigated this hypothesis by comparing
the ability of Lys-g3-MSH with several other melanocortin
peptides to stimulate lipolysis in 3T3-L1 adipocytes. Using
glycerol release as a marker of lipolysis, 3T3-L1 adipocytes
were found to be responsive to all of the melanocortin
peptides tested. As previously described, ACTH and a-MSH
to a lesser extent were both able to stimulate lipolysis with an
EC50 value of 248G45 pM and 4.5G1.35 nM respectively.
NDP-a-MSH, a potent ligand of the MC1, MC3, MC4 and
MC5 receptors (Haskell-Luevano et al. 2001), was observed
to be only weakly lipolytic, although was relatively potent
with an EC50 of 4.19G1.69 pM. The weak activity of NDP-
a-MSH is perhaps not surprising since work by Boston &
Cone (1996) has shown that NDP-a-MSH, although able to
bind with high afﬁnity, does not stimulate an increase in
cAMP accumulation in 3T3-L1 adipocytes. Lys-g3-MSH
produced a maximal response comparable with that of
ACTH, but was not as potent with an EC50 value of
3.56G0.47 nM. The synergistic activity of Lys-g3-MSH in
Figure 4 The potent melanocortin receptor agonist NDP-a-MSH
can reduce the lipolytic activity of a-MSH but not ACTH or Lys-g3-
MSH in 3T3-L1 adipocytes when compared with the lipolytic
activity seen in response to NDP-a-MSH alone. The lipolytic
activity of ACTH, Lys-g3-MSH and a-MSH were determined in the
presence or absence of an increasing dose of NDP-a-MSH. Results
are presented as glycerol release (fold above control), per 4-h
incubation, per 6.3!10
5 cells. The error bars represent mean
GS.E.M.* ( P!0.0001) signiﬁcant difference from the control level.
(b), (c) and (d) are (P!0.0001) signiﬁcantly different from (a). (f), (g)
and (h) are (P!0.05) signiﬁcantly different from (e). (j) is (P!0.05)
signiﬁcantly different from (i).
Figure5 TheMC1,MC3,MC4and MC5receptorantagonistHS024
can reduce the lipolytic activity of a-MSH, but increases the
lipolytic response to Lys-g3-MSH in 3T3-L1 adipocytes when
compared with the lipolytic activity seen in response to HS024
alone. The lipolytic activity of two sub-maximal doses of ACTH,
Lys-g3-MSH and a-MSH were determined in the presence or
100 nM HS024. Results are presented as glycerol release (fold
above control), per 4-h incubation, per 6.3!10
5 cells. The error
bars represent meanGS.E.M. All treatments resulted in a signiﬁcant
(P!0.0001)increase in lipolysiswhen comparedwith controlcells.
Between-treatment differences (with their respective P values) are
shown on the ﬁgure.
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(Pedersen & Brownie 1980). The activity of HSL, in
adipocytes, has been shown to be regulated predominantly
by the reversible phosphorylation of key serine residues
(Fredrikson et al. 1981, Garton et al. 1988, 1989, Garton &
Yeaman 1990, Anthonsen et al.1 9 9 8 ). We therefore
attempted to investigate the actions of Lys-g3-MSH,
ACTH, NDP-a-MSH and a-MSH on the phosphorylation
state of several speciﬁc serine residues in HSL. Only Lys-g3-
MSH and ACTH were able to phosphorylate serine residues
563 and 660 at doses that were compatible with their lipolytic
activities. Both serine 563 and 660 are phosphorylated by
protein kinase A in response to elevated levels of cAMP
resulting in an increase in the activity of HSL by
approximately twofold (Fredrikson et al. 1981). Both
Lys-g3-MSH and ACTH reduced the phosphorylation of
serine 565. This residue is phosphorylated in its basal state and
it has been postulated that when phosphorylated this site acts
to prevent phosphorylation of serine 563 (Garton et al. 1988,
1989, Garton & Yeaman 1990). In this study, the basal
phosphorylation state of serine 565 appears to be reduced by
both Lys-g3-MSH and ACTH perhaps providing evidence
that basal phosphorylation of this residue may prevent the
phosphorylation of serine 563.
Although lipolysis has traditionally been regarded to be
the result of an up-regulation of HSL activity, in the last
10 years it has become clear that activation of HSL is not, on
its own, sufﬁcient for maximal lipolysis to occur (Tansey et al.
2001, 2003, Souza et al. 2002, Sztalryd et al. 2003). A further
protein, perilipin A, which is expressed in the adipocyte and
steroidogenic cells of the adrenal gland, testis and ovary
(Servetnick et al. 1995), must also be activated (Tansey et al.
2001, 2003, Souza et al. 2002, Sztalryd et al. 2003). In
its unstimulated state, perilipin A acts to guard the lipid
droplet from the hydrolytic actions of HSL, but when
stimulated it becomes hyperphosphorylated and moves away
from the lipid droplet surface to allow HSL access to its
substrate (Tansey et al. 2003). We therefore felt that it was
important to investigate the effects of the melanocortin
peptides on perilipin A. Both ACTH and Lys-g3-MSH
caused a signiﬁcant increase in perilipin A phosphorylation,
whereas a-MSH could only promote a minor increase
in phosphorylation and NDP-a-MSH was incapable of
causing perilipin A phosphorylation. Although a-MSH and
NDP-a-MSH are both potent stimulators of MC5-R
mediated cAMP accumulation in heterologous systems
(Haskell-Luevano et al. 2001), it has previously been shown
in 3T3-L1 adipocytes that a-MSH only weakly stimulates,
and NDP-a-MSH is unable to stimulate cAMPaccumulation
(Boston & Cone 1996). Since the phosphorylation of
perilipin A is believed to be primarily a cAMP-dependent
mediated process (Tansey et al. 2003), the limited ability and
inability of these peptides to stimulate cAMP accumulation
may explain their effects on both the phosphorylation of HSL
and perilipin A. Interestingly, the ability of the melanocortin
peptides to phosphorylate perilipin A correlates well with
their lipolytic activities, which may suggest that the ability to
move perilipin A away from the lipid droplet surface is as
important, if not more important than, as the activation of
HSL during the lipolytic process.
Since NDP-a-MSH can bind with high afﬁnity to 3T3-L1
adipocytes but not stimulate cAMP accumulation, Boston &
Cone (1996) used NDP-a-MSH as a receptor antagonist in
an attempt to determine the respective roles played by the
MC2-R and MC5-R in mediating the actions of a-MSH and
ACTH. They observed that NDP-a-MSH was able to block
the actions of a-MSH butnot ACTH (Boston & Cone 1996).
Since NDP-a-MSH has poor afﬁnity for the MC2-R and
high afﬁnity for the MC5-R, they concluded that a-MSH
signals through the MC5-R and that the actions of ACTH are
mediated through the MC2-R (Boston & Cone 1996,
Schioth et al. 1996). Although we found NDP-a-MSH to be
weakly lipolytic, we reasoned that it would still be useful as an
antagonist to dissect the melanocortin receptor responsible for
mediating the lipolytic actions of Lys-g3-MSH.
We found that NDP-a-MSH was able to reduce the
lipolytic activityof a-MSH, but not Lys-g3-MSH or ACTH,
to the level seen in response to NDP-a-MSH alone.
Although our results agree with those of Boston & Cone
suggesting that a-MSH appears to act though the MC5-R
and ACTH through the MC2-R (Boston & Cone 1996), our
results do not clearly support a role for the MC5-R mediating
the actions of Lys-g3-MSH.
In an attempt to clarify these observations, we investigated
the effects of HS024, a known antagonist in the low
nanomolar range of the MC1, MC3, MC4 and MC5
receptors. In a manner similar to NDP-a-MSH, HS024 was
found to be weakly lipolytic and able to antagonise the
lipolytic effects of a-MSH. The compound had a small but
signiﬁcant effect on the lipolytic effects of a low dose (1 nM)
of ACTH but had no effect on lipolysis stimulated by ACTH
at a dose of 10 nM. Since ACTH has a binding afﬁnity for the
MC5-R of around half that of a-MSH (Schioth et al. 1995),
these results raise the possibility that at least some of the
lipolytic actions of ACTH are mediated by the MC5-R.
Interestingly, cells treated with both HS024 and Lys-g3-
MSH at a dose of 1 nM showed an additive effect on lipolysis
when compared with each peptide alone, although HS024
had no effect on the lipolysis stimulated by 10 nM Lys-g3-
MSH. This result could possibly suggest that the two peptides
do not bind to the same site, again, not fully supporting a role
for the MC5-R in mediating the actions of Lys-g3-MSH.
The results from these studies are not easy to interpret;
especially since 3T3-L1 cells constitute a mixed melanocortin
receptor environment and thus the possibility that more than
one receptor has been activated. The simplest explanation is
that the pharmacological properties of MC5-R expressed by
3T3-L1 adipocytes are different from when expressed in
heterologous systems. This hypothesis is indirectly supported
by the observations of Boston & Cone (1996) who found that
NDP-a-MSH, a potent activator of the MC5-R when
expressed in heterologous systems (Haskell-Luevano et al.
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Cone 1996) in 3T3-L1 adipocytes. This, together supported
by our results showing that this peptide is only very weakly
lipolytic, clearly demonstrates that the pharmacology of
endogenously expressed MC5-R is different and it is thus not
inconceivable that it could have a higher afﬁnity for g-MSH
peptides than previously reported.
Another explanation is that the lipolytic actions of Lys-g3-
MSH are being mediated through an uncharacterised
melanocortin receptor. Although this seems unlikely, other
studies have provided pharmacological evidence to support
the idea that a further MC-R exists. Experiments analysing
the actions of g-MSH peptides in the pituitary suggest the
existence of a G-protein-coupled receptor that is pharma-
cologically distinct from any member of the melanocortin
receptor family in this tissue (Lorsignol et al. 1999, Langouche
et al. 2001, 2002). Li et al. (1996) have shown that the centrally
mediated pressor and tachycardic actions of g-MSH do not
appear to be mediated through any of the ﬁve known
melanocortin receptors.
Although the effects of Lys-g3-MSH in the adrenal gland
have been clearly demonstrated and our results suggest that its
actions are not limited to the adrenal gland, the physiological
relation of Lys-g3-MSH to the other peptides derived from
POMC in vivo in both rodents and humans is still unclear.
However, our results do suggest that it may play a wider
peripheral role than has previously been thought. In addition,
the receptor through which these actions are mediated, and
whether Lys-g3-MSH can exert actions on other tissues that
express HSL and possess binding sites, remains to be
determined and warrants further investigation.
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